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Aims Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure
(HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5mg bid compared with placebo
(with standard care) after an exacerbation of HF in patients with reduced ejection fraction (HF-rEF) and documented
coronary artery disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods This is an international prospective, multicentre, randomized, double-blind, placebo-controlled, event-driven study
of approximately 5000 patients for a targeted 984 events. Patients must have a recent symptomatic exacerbation of
HF, increased plasma concentrations of natriuretic peptides (B-type natriuretic peptide ≥200 pg/mL or N-terminal
pro–B-type natriuretic peptide ≥800 pg/mL), with left ventricular ejection fraction ≤40% and coronary artery
disease. Patients requiring anticoagulation for atrial fibrillation or other conditions will be excluded. After an index
event (overnight hospitalization, emergency department or observation unit admission, or unscheduled outpatient
parenteral treatment for worsening HF), patients will be randomized 1:1 to rivaroxaban or placebo (with standard
of care). The primary efficacy outcome event is a composite of all-cause mortality, myocardial infarction or stroke.
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The principal safety outcome events are the composite of fatal bleeding or bleeding into a critical space with potential
permanent disability, bleeding events requiring hospitalization and major bleeding events according to International
Society on Thrombosis and Haemostasis bleeding criteria.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion COMMANDER HF is the first prospective study of a target-specific oral antithrombotic agent in HF. It will provide
important information regarding rivaroxaban use following an HF event in an HF-rEF patient population with coronary
artery disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
The prevalence of heart failure (HF) has increased progressively
over the past several decades owing primarily to a reduction
in myocardial infarction (MI) mortality and a steady ageing of
the population around the world.1 Heart failure with reduced
ejection fraction (HF-rEF) is a final common pathway for many
cardiovascular diseases, notably coronary artery disease (CAD).2
Once established, HF-rEF progresses through activation of a variety
of pathways that adversely affect cardiac structure and function.
Currently, the most effective pharmacological therapies for
HF-rEF target the activation of the renin–angiotensin–aldosterone
system and the 𝛽-adrenergic sympathetic nervous system that
occurs in HF.3,4 However, even with these treatments, morbidity
and mortality remain unacceptably high and increase further after
episodes of acute decompensation.5–7
Because thrombotic events are increased in HF patients,8,9 clini-
cal and observational studies have explored chronic oral antithrom-
botic treatment strategies. A recent comprehensive review of war-
farin anticoagulation in HF patients in normal sinus rhythm10 that
included both the WASH11 and HELAS12 randomized trials found
‘no convincing evidence that oral anticoagulant therapy modifies
mortality or vascular events in patients with HF and sinus rhythm.’
In addition, the WARCEF trial,13 which compared the effects of
warfarin vs. aspirin on a composite endpoint of ischaemic stroke,
intracerebral haemorrhage or death from any cause, showed no
significant differences in outcome. A reduction in ischaemic stroke
risk with warfarin was balanced by increased risk of bleeding.
Nonetheless, thrombin plays a critical role in multiple patho-
physiological processes that occur in CAD patients with recent
symptomatic decompensation of HF-rEF.14 Targeted reduction of
thrombin generation with rivaroxaban, a Factor Xa inhibitor, rather
than non-selective depletion of multiple vitamin K–dependent
clotting factors with warfarin, may hold promise. Supporting
this concept, analysis of 5284 patients with chronic HF from
Val-HeFT and GISSI-HF trials demonstrated the clinical impor-
tance of ongoing myocardial injury in HF.15 Increased plasma
cardiac troponin T detected by high-sensitivity assay (hs-cTnT)
predicted increased all-cause mortality (ACM) after adjustment
for conventional risk factors and baseline hs-cTnT and N-terminal
pro–B-type natriuretic peptide (NT-proBNP; 59% increase in
Val-HeFT and 88% increase in GISSI-HF). Recognition of the
importance of troponin elevations16–18 in HF has drawn attention ..
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.. to the thrombin-related pathways that may be associated with
ongoing myocyte injury, including inflammation, endothelial dys-
function and microvascular thrombosis.14,16,19,20 A growing body
of evidence suggests that thrombin provides a common element
of ‘crosstalk’ that links these pathways.19 However, the poten-
tial benefits of antithrombotic therapy in HF patients remain
unclear.21
Inflammation
Heart failure is intricately linked to elevation in pro-inflammatory
cytokines and abnormalities in circulating lymphocyte subsets.22 In
more than 1700 patients with HF in the Val-HeFT trial, increasing
plasma concentrations of growth differentiation factor (GDF)-15
(evidence of inflammation) over 12months were independently
associated with higher future morbidity and mortality, supporting
a role for heightened inflammatory activity in the progression
of HF.23
Endothelial dysfunction
The presence and importance of endothelial dysfunction in patients
with CAD is well documented.24 In 259 subjects with New York
Heart Association II–IV HF and a median follow-up of just over
1 year, Katz et al.25 demonstrated that decreased brachial arterial
flow-mediated dilation (FMD) and decreased exhaled NO pro-
duction were associated with increased risk of death or urgent
transplantation after adjustment for other known HF prognostic
factors (age, aetiology of HF, functional class, left ventricular ejec-
tion fraction). In a study of 245 patients with stable HF and impaired
FMD, optimal medical therapy for 6months failed to reverse
impaired FMD in 53% (130 patients), and persistently impaired
FMD increased the 3-year risk for cardiac events by threefold.26
Thrombosis
Evidence for increased thrombin activity and microvascular throm-
bosis in HF and an association with increased mortality continues
to accumulate. Patients with HF have increased thrombin activ-
ity (D-dimer, thrombin-antithrombin complexes) compared with
controls.27,28 A study of 174 patients with systolic HF demon-
strated that elevated thrombin activity (D-dimer >1435 ng/mL)
was associated with greater than threefold increase in mortality.29
Thus, a growing body of evidence provides the clinical rationale
for modulation of thrombin generation in HF-rEF. In contrast,
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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inhibition of Factor Xa with rivaroxaban is associated with an
increased risk of bleeding. The COMMANDER HF trial was
designed to test the hypothesis that rivaroxaban could reduce
the composite of ACM, stroke and MI in patients with HF-rEF
and documented CAD who had experienced a recent acute
decompensation of their condition with an acceptable risk of
bleeding.
Rivaroxaban
Rivaroxaban is a specific inhibitor of activated Factor X (Factor Xa
or FXa). In the clotting cascade, exposure of blood to tissue fac-
tor (TF) activates circulating Factor VII. Factor VII complexes with
Factor X, and the complex initiates formation of the prothrom-
binase complex that includes FXa, Factor Va, and calcium. The
prothrombinase complex cleaves prothrombin to generate throm-
bin. Because FXa activation leads to an amplifying burst of thrombin
generation,30 specifically targeting FXa may offer a new approach
to interrupt the negative feedback cycles associated with increased
thrombin generation in HF-rEF.
In 12 healthy volunteers receiving single doses of rivaroxaban
(5mg or 30mg) or placebo, both doses of rivaroxaban potently
inhibited thrombin generation for 24 h.31 In 51 patients who had
undergone elective hip or knee replacement 6–8 h before receiving
either dalteparin (2500–5000U QD) or rivaroxaban (10mg QD),
effective inhibition of ex vivo thrombin generation was consistently
achieved with rivaroxaban, and inhibition was greater than with
dalteparin.32 In 18 HF patients receiving rivaroxaban 10mg QD
or placebo, thrombin generation after 7 days (as measured by
prothrombin fragment 1.2) was reduced with rivaroxaban.33 These
data demonstrate that rivaroxaban effectively inhibits thrombin
generation across a wide spectrum of doses.
In the ATLAS-2 trial,34 both rivaroxaban 5mg bid and rivaroxa-
ban 2.5mg bid reduced the composite efficacy endpoint; however,
the 2.5mg bid dose was associated with fewer episodes of major
bleeding. In addition, an unpublished subgroup analysis of ATLAS-2
(Janssen Research & Development, LLC, Raritan, NJ, USA; data
on file), although subject to all the limitations of retrospective ad
hoc subgroup analysis, showed that in patients clinically diagnosed
as having HF at the time of their acute coronary syndrome (ACS)
event, rivaroxaban 2.5mg bid reduced the primary outcome event
of cardiovascular death, MI or stroke after a mean follow-up of
13months from 18.6% with placebo to 11.6% with rivaroxaban
2.5mg bid (P< 0.001), reduced cardiovascular death from 10.4%
with placebo to 5.2% with rivaroxaban 2.5mg bid (P< 0.001),
and reduced death from any cause from 11.1% with placebo to
5.3% with rivaroxaban 2.5mg bid (P< 0.001). In this subgroup,
major bleeding, according to Thrombolysis In Myocardial Infarc-
tion (TIMI) criteria, occurred in slightly fewer patients receiving
rivaroxaban 2.5mg bid than placebo (0.4% vs. 0.7%).
Rivaroxaban 2.5mg bid is approved in Europe for the treatment
of biomarker-positive patients after an ACS, and is undergoing
additional study in the USA. Based on the data and the consid-
erations above, a dose of rivaroxaban 2.5mg bid was chosen for
the COMMANDER HF trial as the most likely to offer an optimal
combination of safety and efficacy. ..
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.. Study design
Study objectives and outcome events
The primary efficacy objective is to demonstrate that rivaroxaban
is superior to placebo in subjects with HF and significant CAD,
who are receiving standard care, in reducing the risk of the com-
posite of ACM, MI or stroke following a recent exacerbation of
HF. The primary efficacy outcome event is the composite of ACM,
MI or stroke. The principal safety outcome event is the composite
of fatal bleeding or bleeding into a critical space with a potential
for permanent disability.
Major secondary efficacy outcomes include the composite
of cardiovascular mortality and rehospitalization for worsening
of HF, and the separate outcomes of cardiovascular mortality,
rehospitalization for worsening of HF, and rehospitalization for
cardiovascular events. Additional bleeding outcomes are bleeding
events requiring hospitalization and major bleeding events accord-
ing to the International Society on Thrombosis and Haemostasis
(ISTH) bleeding criteria.35
Prespecified exploratory analyses will evaluate symptomatic
deep vein thrombosis, symptomatic pulmonary embolism and
benefit–risk balance.
Design
COMMANDER HF (ClinicalTrials.gov Identifier: NCT01877915)
is an international prospective, randomized, double-blind, placebo-
controlled, event-driven, parallel-group comparison between
rivaroxaban and placebo (Figure 1). The study includes a screening
phase, a double-blind treatment phase and follow-up after the
sponsor-announced global treatment end date (GTED, defined as
the date when 984 primary efficacy outcome events are predicted
to have occurred). Subjects will be followed for a minimum of
approximately 7months and a maximum of 31months.
Ethics approval
COMMANDER HF will be conducted in keeping with Good Clini-
cal Practice guidelines, the principles outlined in the Declaration of
Helsinki, and applicable local laws and regulations. All participating
centres/countries must obtain approval from appropriate indepen-
dent ethics committees or institutional review boards, and patients
must give written informed consent.
Patient population
The COMMANDER HF study will enroll adult (≥18 years old)
patients, who are clinically stable up to 30 days after a symptomatic
index event, defined as an exacerbation of HF symptoms requiring:
(1) hospitalization, emergency room or observation unit admis-
sion capable of treating with intravenous medications, or (2) an
unscheduled outpatient visit requiring parenteral therapy. Patients
must have HF documented by a level of NT-proBNP≥800 pg/mL or
B-type natriuretic peptide (BNP) ≥200 pg/mL (obtained between
the onset of the index event and randomization), must have left
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Study design. GTED, global treatment end date; R, randomization; HF, heart failure; HF-rEF, heart failure with reduced ejection
fraction; CAD, coronary artery disease.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18 years of age or older
Documented symptomatic HF for ≥3months before screening
with a minimum of an overnight stay (i.e. staying past midnight)
in a hospital, emergency department or medical facility and a
documented LVEF of ≤40% within 1 year before randomization
or during index hospitalization, and evidence of significant CAD
Medically stable in terms of HF clinical status (ambulatory and
receiving no IV medications) at randomization, receiving
appropriate HF treatment at the appropriate dosing per
guidelines, and receiving appropriate CAD treatment per
guidelines
Completed all prophylactic anticoagulation before randomization
Signed informed consent
≥200 pg/mL BNP or ≥800 pg/mL NT-proBNP during their index
hospitalization, or after discharge from index hospitalization but
before randomization
Bleeding risk or any severe concomitant disease (e.g. atrial fibrillation or
acute MI during index hospitalization)
Planned cardiac surgery within 28 days before or after randomization,
excluding PCIs and electrophysiological devices
History of severe valvular disease, chronic episodes of ventricular
tachycardia, severe peptic ulcer disease, or HIV
Stroke within 90 days of randomization
HF caused by postpartum, infection, substance abuse, alcohol, infiltrative
disease, or transient reversible condition
Cardiogenic shock at randomization
eGFR <20mL/min
Anticipated life expectancy <6months
Acute endocarditis
Currently on haemofiltration or dialysis or known significant liver disease
Anaemia (Hb <8 g/dL) or severe thrombocytopenia (platelets <50 000/μL)
at screening
Hospitalized >21 days during index hospitalization
Planned IV intermittent outpatient positive inotropic drug treatment
HF, heart failure; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro–B-type natriuretic peptide;
MI, myocardial infarction; PCI, percutaneous coronary intervention; HIV, human immunodeficiency virus; eGFR, estimated glomerular filtration rate; Hb, haemoglobin.
ventricular ejection fraction ≤40%, and must have documented sig-
nificant CAD according to predefined criteria (Table 1).
Patients with significant valvular heart disease or atrial fibrillation
before randomization will be excluded, as will those with other
indications for chronic anticoagulation (Table 1).
Patients will have follow-up visits at week 4, week 12, and every
12weeks for assessment of outcome events and safety. When it
is estimated that 984 primary outcome events have occurred, the
investigator sites will be notified of the GTED, and patients will be .
..
..
..
..
..
..
..
..
..
..
..
.. required to have a final visit within 30 days of the GTED. Patients
who discontinue study drug prematurely will continue follow-up
with the investigator every 12weeks until GTED.
Study drug
Patients randomized to rivaroxaban will receive rivaroxaban 2.5mg
orally twice daily without adjustment for renal function, consistent
with the dose approved in the European Union for post-ACS
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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management. Subjects are advised to take the study drug at
approximately the same times each day.
Concurrent interventions
The use of strong inhibitors of both cytochrome P450 3A4
and P-glycoprotein (e.g. ketoconazole, itraconazole, voricona-
zole, posaconazole, or human immunodeficiency virus protease
inhibitors), Factor IIa inhibitors, low molecular weight hep-
arin, or unfractionated heparin is prohibited. Strong inducers
of cytochrome P450 3A4 are prohibited within 4 days before
randomization or during the study. Patients who are receiv-
ing concomitant non-steroidal anti-inflammatory drugs, platelet
aggregation inhibitors, or other antithrombotic agents should be
monitored carefully. Patients at risk for ulcerative gastrointesti-
nal disease or gastrointestinal bleeding can receive prophylactic
treatment with proton pump inhibitors (except omeprazole or
esomeprazole) at the investigator’s discretion. These medications
will be captured as concomitant medications on the electronic
case report form.
Outcome definitions
Primary efficacy outcome
The primary efficacy outcome is the composite of ACM, MI or
stroke. Outcome events will be as reported by the investigator
and will not be independently adjudicated.
All-cause death and cardiovascular death
Deaths are assigned by the investigator to either cardiovascular
(e.g. stroke, MI or haemorrhage) or non-cardiovascular (e.g. malig-
nancy, infectious disease or trauma) causes. Instances of sudden
cardiac death, involving cardiac arrest, accompanied by symptoms
of myocardial ischaemia, abnormal electrocardiographic findings,
and/or evidence of fresh thrombus by coronary angiography and/or
autopsy (i.e. fatal MI) will be classified as cardiovascular.
Myocardial infarction
In the absence of percutaneous coronary intervention or coronary
artery bypass graft, cases involving rise and/or fall of cardiac
biomarkers (preferably troponin) with ≥1 value above the 99th
percentile of the upper reference limit will be classified as MI if
accompanied by myocardial ischaemia, demonstrated by ≥1 of the
following: ischaemic signs, development of pathological Q waves or
changes indicative of new ischaemia (i.e. new ST-T changes or new
left bundle branch block) on electrocardiogram, imaging evidence
of new loss of viable myocardium, or new regional wall motion
abnormality. The definition of MI as a clinical outcome event also
includes criteria for periprocedural biomarker elevations around
percutaneous coronary intervention or coronary artery bypass
graft.
Stroke
Stroke is defined as an abrupt onset of a focal neurological deficit
that is not initiated by an identifiable non-vascular cause (i.e. brain ..
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.. tumour or trauma) and that either is associated with symptoms
lasting >24 h or results in death within 24 h of symptom onset.
Computed tomography and/or magnetic resonance imaging will
be used to subclassify strokes (ischaemic, haemorrhagic or sub-
arachnoid). Subdural and epidural haematoma will be considered
intracranial haemorrhages, but will not be classified as a haemor-
rhagic stroke. Cases in which imaging is unavailable or inconclusive
will be classified as stroke of uncertain cause. Instances of stroke
thought to be the primary cause of or directly leading to death (i.e.
fatal stroke) will be classified as cardiovascular death.
Secondary efficacy outcomes
Secondary efficacy outcomes include the composite of cardio-
vascular mortality and rehospitalization for worsening of HF, and
the separate outcomes of cardiovascular mortality, rehospitaliza-
tion for worsening of HF, and rehospitalization for cardiovascular
events.
Safety evaluations
An independent data monitoring committee (IDMC) will monitor
data on an ongoing basis to ensure the continuing safety of the
subjects enrolled in this study and to meet efficacy objectives.
Major bleeding
Major bleeding events will be defined according to the ISTH
criteria35: clinically overt bleeding that leads to a transfusion of
≥2 units of packed red blood cells or whole blood, or that is asso-
ciated with a fatal outcome or involves a critical site. Intracranial
bleeding will be classified as either a haemorrhagic stroke, sub-
arachnoid haemorrhage, or subdural or epidural haemorrhage.
Non-major bleeding
Non-major bleeding events are defined as overt bleeding not
meeting the criteria for major bleeding.
Sample size and statistical methods
This study aims to observe occurrences of the primary efficacy
event in 984 unique randomized subjects, on or before the GTED
to have 90% power to detect a 20% relative risk reduction (RRR)
in the composite of ACM, MI or stroke at a 5%, 2-sided statistical
significance level. GTED is defined as the date when 984 primary
efficacy outcome events are predicted to have occurred. Approxi-
mately 5000 subjects will be randomized.
The IDMC reviews unblinded safety data periodically. If neces-
sary, or requested by the IDMC, subject-level unblinded data may
be provided to the IDMC. In addition, the IDMC will review results
of an interim analysis after approximately 500 subjects have expe-
rienced primary efficacy events and will recommend whether the
study should be terminated prematurely because of overwhelming
benefit or futility.
The primary statistical hypothesis will be tested using a log-rank
test, stratified by country.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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The primary analysis will be based on the analysis set defined
by the intention-to-treat subject population and the up-to-GTED
observational period (up to the cut-off date to be specified for the
interim analysis).
The RRR will be estimated using a Cox proportional hazards
model, stratified by country, with treatment (as randomized)
as the only covariate. The point estimate and corresponding
95% confidence interval (CI) for the hazard ratio (HR; rivaroxaban
to placebo) will be reported.
If superiority of rivaroxaban over placebo in reducing the risk of
the primary efficacy outcome event is established, treatment effects
in secondary outcome events will be tested subsequently in the
following hierarchical order: (1) composite of cardiovascular mor-
tality or rehospitalization for worsening of HF; (2) cardiovascular
mortality; (3) rehospitalization for worsening of HF; (4) rehospital-
ization for cardiovascular events.
Statistical significance is required before testing the next hypoth-
esis in the hierarchical test procedure. These secondary outcome
events will be analysed using time-to-event analysis, as described
above for the primary outcome event.
Homogeneity of treatment effects, both in RRR and direction, in
the following prespecified subgroups will be assessed: age, sex, left
ventricular ejection fraction, estimated glomerular filtration rate,
baseline troponin, history of diabetes, stroke, MI and hypertension,
body mass index, aspirin use, race and geographic region.
The principal safety evaluation outcome event is the composite
of fatal bleeding, or bleeding into a critical space with potential
for permanent disability. Time to the first occurrence of the
principal safety outcome events will be compared using a Cox
proportional hazards model, stratified by country, with treatment
as the only covariate. The analysis will be conducted for the
analysis set defined by the on-treatment observational period and
the safety population. Subjects will be analysed according to study
drug received. If a subject receives both drugs, the subject will be
analysed as randomized.
Discussion
COMMANDER HF has several key elements among its inclusion
criteria, such as the requirements for documented CAD, for an
‘index event’ with clinical decompensation of HF, and for qualifying
plasma concentrations of natriuretic peptides.
The requirement for CAD reflected a consensus among the
investigators that evidence for the contribution of thrombotic
mechanisms to adverse outcomes in patients with CAD was
stronger than for non-ischaemic aetiologies of HF.22,36 Requiring
a recent worsening HF event and increased plasma concentra-
tions of natriuretic peptides confirms that the patients have HF,
that their needs were unmet by previous therapy, and identifies
patients at increased risk of further events.6,7,37 In response to
changing patterns of care for HF patients, the definition of an
index event was modified in a protocol amendment that elimi-
nated the requirement of an overnight stay for treatment, and the
window for randomization after the index event was extended to
30 days. ..
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.. COMMANDER HF is limited to subjects with HF-rEF because of
the uncertainties surrounding the diagnostic criteria, management,
and event rates for HF-pEF.
As ACM is expected to be the primary driver of the efficacy
outcome event, the sponsor and steering committee agreed that a
complex and expensive adjudication process would not be required
for this trial.
Importantly, COMMANDER HF is not another trial of oral
anticoagulation in HF but rather an intervention to modulate
thrombin-mediated crosstalk, a potential driver of multiple negative
feedback cycles, including inflammation, endothelial dysfunction,
and thrombosis, in patients with HF-rEF and CAD.
The COMMANDER HF study will be the first double-blind,
placebo-controlled, randomized clinical trial designed to provide
statistically robust results that explore the role of a targeted
antithrombin strategy in patients with a recent exacerbation of
HF-rEF and coexisting CAD.
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